IPGA12: A potential First-in-class antagonist antibody for autoimmune disease


The target of IPGA12 is a leukocyte immunoglobulin-like receptor that plays a crucial role in driving autoimmune diseases, including psoriasis, multiple sclerosis (MS), inflammatory bowel disease (IBD), and rheumatoid arthritis (RA). Activation of the target triggers proinflammatory cytokines, contributing to disease pathogenesis. IPGA12 functions as an antagonist antibody that blocks target-mediated signalling, offering potential therapeutic benefits in attenuating the progression of these autoimmune diseases.

Mechanism of Action


■ Upon encountering its ligand, the activation of the target leads to the activation of the ITAM motif and subsequent signalling pathways, such as Syk and PI3K activation.

■ This activation further triggers downstream pathways, including AKT, NFAT, Ras/ERK, NF-κB, JNK, and MAPK, promoting effector function, proliferation, survival, maturation, and cytokine release associated with autoimmune disease progression.